Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Regorafenib + nivolumab in MMR proficient advanced CRC

Richard D. Kim • 3 Jul 2020
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer Antibodies Nivolumab Regorafenib

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Richard D. Kim

2:15
The role of immunotherapy in cholangiocarcinoma
Richard D. Kim et al. • 26 Jan 2023
2:40
Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer
Richard D. Kim et al. • 26 Jan 2023
1:55
The latest in targeted therapies for advanced colorectal cancer
Richard D. Kim et al. • 26 Jan 2023
2:44
Biomarkers of treatment response in patients with MMR-proficient CRC
Richard D. Kim et al. • 26 Jan 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals